A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Patients With RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

STUDY GOAL: To learn whether ixazomib in combination with dexamethasone controls multiple myeloma longer than pomalidomide in combination with dexamethasone in patients with Relapsed Refractory Multiple Myeloma whose disease is resistant to lenalidomide but should be sensitive to proteasome inhibitors. The study is for patients who have already received at least two lines of therapy, including lenalidomide and a proteasome inhibitor, and are resistant to lenalidomide but not resistant to proteasome inhibitors.

Learn more about this study

YOU MAY BE ELIGIBLE
TO PARTICIPATE IF YOU:

  • Are 18 years of age or older
  • Have Relapsed and/or Refractory Multiple Myeloma (RRMM)
  • Your disease is resistant to lenalidomide
  • Have received at least 2 consecutive cycles of bortezomib or carfilzomib, and either:
    • Achieved at least a partial response (PR) and did not have progressive disease (PD) during treatment or within 60 days after the last dose
    • OR
    • Had bortezomib and/or carfilzomib intolerance without PD upon the start of the next regimen
  • Meet other eligibility criteria
LEARN MORE ABOUT ELIGIBILITY CRITERIA

ABOUT MULTIPLE
MYELOMA

An overview of the condition,
its symptoms, and
whom it affects.

GO

WHAT IS A
CLINICAL STUDY?

Learn about the purpose
of clinical studies, how
they are set up, and
why they are important.

GO
To learn more about
this study, call:
1-844-662-8532
Monday–Friday 9am–7pm ET

After hours?

Provide your contact information and we'll call you back.